Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

 with expert commentary and insights on new studies.

Readout 360

 with expert commentary and insights on new studies.


1rem

Oncology experts present and discuss recent data on frontline therapy options and outcomes for advanced metastatic clear cell and non-clear cell renal cell carcinoma, including considerations around optimal therapy for patients based on risk factors and disease sites, with a focus on understanding biology to develop improved histology-directed treatment approaches.

Updates in the Treatment of Advanced RCC: Highlights from ASCO GU 2024

Three oncologists review recent clinical trial data presented at ASH 2023 on treatments for newly diagnosed multiple myeloma patients.

Updates in the Treatment of Newly Diagnosed Multiple Myeloma from ASH 2023

Three medical oncologists review recent clinical trial data presented at ESMO 2023 on treatments for patients with non–small cell lung cancer.

Updates in the Treatment of Non–Small Cell Lung Cancer: Highlights from ESMO 2023

Expert panelists review clinical data from recent meetings regarding the updated management of renal cell carcinoma and consider how their real-world practice has been impacted. 

Evolving the Treatment of Renal Cell Carcinoma: Highlights from KCRS and ASCO 2023

Expert GU oncologists discuss recent data updates in the treatment of renal cell carcinoma from the ASCO 2023 Annual Meeting.

New Findings on the Treatment of Renal Cell Carcinoma: Highlights from ASCO 2023

Three experts in gynecologic oncology review and discuss data updates from The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer 2023.

Highlights from The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer 2023

Shaji Kumar, MD, Sandy Wong, MD, and Alexander Lesokhin, MD, review key data updates on the use of bispecific antibodies for the treatment of multiple myeloma presented at ASH 2022 and other recent meetings, and discuss how recent clinical trials have influenced treatment approaches in both the transplant-eligible and -ineligible patient populations.

Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond

A panel of experts review key data updates in renal cell carcinoma (RCC) from the International Kidney Cancer Association (IKCS) and European Society for Medical Oncology (ESMO) 2022 meetings and discuss how recent clinical trials are shaping the treatment of clear cell and non-clear cell RCC in clinical practice.

Updates in the Treatment of Renal Cell Carcinoma: Highlights from IKCS and ESMO 2022

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.

Refining Combination Strategies in Metastatic RCC